Your Health, We Care
Zydelig, in combination with rituximab, is indicated for the treatment of patients with relapsed chronic lymphocytic leukemia who are considered suitable for rituximab monotherapy due to other comorbidities.
Zydelig is not indicated and is not recommended for first-line treatment in any patients, including those with chronic lymphocytic leukemia, small lymphocytic lymphoma, follicular lymphoma, and other indolent non-Hodgkin lymphomas.
Zydelig is not indicated and is not recommended for use in combination with bendamustine and rituximab, or in combination with rituximab for the treatment of patients with follicular lymphoma, small lymphocytic lymphoma, and other indolent non-Hodgkin lymphomas.
FDA，2022.02
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
